Enhanced ITGA3 expression induced by helicobacter pylori infection facilitates gastric cancer progression via NF-κB and Smad4
Related Experiment Video
Updated: Jun 5, 2026

Mouse Models Of Helicobacter Infection And Gastric Pathologies
Published on: October 18, 2018
Yuanxin Xing1,2, Yan Chu3, Wenshuai Zhu1
1Research Center of Basic Medicine, Jinan Central Hospital, Shandong First Medical University, Jinan, 250013, People's Republic of China.
Abstract:
Helicobacter pylori (H. pylori) infection is a key risk factor in the onset and progression of gastric cancer (GC). The integrin subunit alpha 3 (ITGA3) is frequently upregulated in various malignancies and may influence cell proliferation and metastasis under specific conditions. However, the mechanisms that govern ITGA3 activation and its role in the inflammation-driven transformation of GC remain poorly understood. This study explores the impact of ITGA3 in response to H. pylori infection and its involvement in gastric tumorigenesis. Elevated ITGA3 expression was observed in gastric tissues and in GC cells exposed to H. pylori, and was associated with enhanced malignant phenotypes in vitro and increased tumor growth in vivo. Mechanistically, ITGA3 appears to promote GC progression, at least in part, through activation of the NF-κB/mTOR signaling axis and enhancement of TGF-β-related signaling, thereby contributing to tumor proliferation, epithelial-mesenchymal transition (EMT), and migration. Additionally, H. pylori infection led to an increase in p-STAT3 expression, which transcriptionally upregulates ITGA3, thereby further enhancing its pro-tumorigenic effects. This study suggests a previously underappreciated role for ITGA3 in H. pylori-associated GC. H. pylori infection induces p-STAT3 activation, driving ITGA3 expression at the transcriptional level. In turn, ITGA3 promotes GC progression by concurrently activating the NF-κB/mTOR and TGF-β signaling pathways, facilitating tumor cell proliferation, EMT, and migration, and thereby accelerating the malignancy of GC. These findings suggest that the ITGA3/NF-κB/mTOR/TGF-β axis may represent a potential therapeutic target for H. pylori-positive GC.
More Related Videos
09:05High Resolution Electron Microscopy of the Helicobacter pylori Cag Type IV Secretion System Pili Produced in Varying Conditions of Iron Availability
Published on: November 21, 2014
11:48Mouse- and Human-derived Primary Gastric Epithelial Monolayer Culture for the Study of Regeneration
Published on: May 7, 2018
Related Concept Videos
Gastritis II: Pathophysiology
Peptic Ulcer Disease II: Pathophysiology
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds to M3...
Gastritis-II: Pathophysiology
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...